I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals secured a final arbitration award exceeding RMB 100 million against Juventas at the Hong Kong International Arbitration Centre. The tribunal rejected Juventas' breach claims, ruling that Juventas wrongfully terminated the CNCT-19 commercialization agreements in March 2024. The award covers wasted costs, interest, arbitration fees, and most legal expenses.
- CASI Pharmaceuticals won a final arbitration award against Juventas at the Hong Kong International Arbitration Centre over CNCT-19 commercialization agreements. * The tribunal rejected all Juventas breach claims, ruling Juventas wrongfully terminated the agreements in March 2024. * Award covers wasted costs, interest from the termination date, arbitration costs, and most legal fees, totaling well over RMB 100 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-083702), on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here